Attached files
file | filename |
---|---|
EX-99.2 - ABSTRACT - Cellular Biomedicine Group, Inc. | cbmg_992.htm |
8-K - CURRENT REPORT - Cellular Biomedicine Group, Inc. | cbmg_8k.htm |
EXHIBIT
99.1
Cellular Biomedicine Group (CBMG) Announces Publication Titled
“Target cell killing effects of CD20 targeting chimeric
antigen receptor T cells derived from the type II anti-CD20
antibody” in Conjunction with 2017 ASCO Annual
Meeting
SHANGHAI, China and CUPERTINO, Calif., May 19,
2017 /GlobeNewswire/ — Cellular Biomedicine Group
Inc. (NASDAQ: CBMG) (“CBMG” or the
“Company”), a clinical-stage biopharmaceutical firm
engaged in the development of effective immunotherapies for cancer
and stem cell therapies for degenerative diseases, today announced
the publication of an abstract exploring the application of B-cell
antigen, CD20, for targeted Chimeric Antigen
Receptor T cells (CAR-T)
therapy. The abstract has been published in conjunction with the
2017 American Society of Clinical Oncology (ASCO) Annual Meeting in
Chicago, June 2 – 6, 2017.
Abstract e14548, J Clin Oncol 35,
2017 - Target cell killing
effects of CD20 targeting chimeric antigen receptor T cells derived
from the type II anti-CD20 antibody.
The complete text of the abstract can be found at
http://abstracts.asco.org/199/AbstView_199_192206.html
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc.
(NASDAQ: CBMG) develops proprietary cell therapies for the
treatment of cancer and degenerative diseases. We conduct
immuno-oncology and stem cell clinical trials in China using
products from our integrated GMP laboratory. Our GMP facilities in
China, consisting of twelve independent cell production lines, are
designed and managed according to both China and U.S. GMP
standards. CBMG recently commenced two Phase I human clinical
trials in China using CAR-T to treat Refractory Diffuse Large
B-cell Lymphoma (DLBCL), a Phase I human clinical trial to treat
relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia
(ALL), as well as an ongoing Phase I trial in China for
AlloJoinTM
(CBMG’s
“Off-the-Shelf” Allogeneic Human Adipose-derived
Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis
(KOA). CBMG was recently awarded $2.29 million from the California
Institute for Regenerative Medicine (CIRM) to support pre-clinical
studies of AlloJoinTM
for Knee Osteoarthritis in the United
States. The Company also recently announced a strategic partnership
with GE Healthcare Life Sciences China to establish a joint
technology laboratory to develop control processes for the
manufacture of CAR-T and stem cell therapies. To learn more about
CBMG, please visit www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include risks
inherent in doing business, trends affecting the global economy,
including the devaluation of the RMB by China in August 2015 and
other risks detailed from time to time in CBMG’s reports
filed with the Securities and Exchange Commission, quarterly
reports on form 10-Q, current reports on form 8-K and annual
reports on form 10-K. Forward-looking statements may be identified
by terms such as "may," "will," "expects," "plans," "intends,"
"estimates," "potential," or "continue," or similar terms or the
negative of these terms. Although CBMG believes the expectations
reflected in the forward-looking statements are reasonable, they
cannot guarantee that future results, levels of activity,
performance or achievements will be obtained. CBMG does not have
any obligation to update these forward-looking statements other
than as required by law.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 408-973-7884
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Citigate Dewe
Rogerson
+1 347 481-3711
vivian.chen@citigatedr.com
CBMG Press
Room
|
www.CellBioMedGroup.com
|
PR2017014
|